Your session is about to expire
← Back to Search
AVP-786 for Alzheimer's-related Agitation
Study Summary
This trial will test whether AVP-786 is better than placebo at treating Alzheimer's-related agitation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 387 Patients • NCT02442765Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a caregiver who can help me with my treatment and follows the study rules.My agitation is not due to Alzheimer's, pain, psychiatric disorders, or delirium.I have been diagnosed with Alzheimer's disease based on specific criteria.I need medication for agitation after trying other non-medication methods.My dementia is not mainly caused by Alzheimer's disease.You have myasthenia gravis.My agitation is officially recognized by a major health organization.
- Group 1: Placebo
- Group 2: AVP-786
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment have an age limit?
"This trial only accepts patients that are between 50 and 90 years old. In contrast, there are 45 clinical trials for children and 770 trials for senior citizens."
When might AVP-786 be cleared for public distribution by the FDA?
"AVP-786 falls into the Phase 3 category, which means that while there is some data supporting efficacy, there is also a fair amount of data that supports safety. We believe that AVP-786 is safe and gave it a score of 3."
At how many hospitals is this experiment being conducted?
"This study is currently enrolling patients at 39 different locations, including Clinical Research Site #840-049 in West Palm Beach, Clinical Research Site #840-046 in Los Angeles, and Clinical Research Site #840-066 in San Diego."
If I wanted to join this research project, would that be possible?
"This trial, which is looking for 750 total participants, is currently enrolling individuals that are between the ages of 50 and 90 and have a dementia diagnosis. Additionally, patients must meet the following conditions: have probable Alzheimer's disease according to the 2011 NPI-AA working group criteria, have moderate-to-severe agitation that interferes with their day-to-day life for at least 2 weeks, require pharmacotherapy for agitation after other interventions have failed, meet the IPA provisional definition of agitation, meet a predetermined blinded eligibility criterion, have a caregiver who is willing and able to help with study procedures, spends 2+ hours per"
Is it possible to still join this clinical trial?
"Yes. The clinical trial is recruiting participants at the moment. The study was posted on 2020-09-03 and was last edited on 2022-10-26. They are looking for 750 participants total, with recruitment happening at 39 different locations."
How many people are undergoing this trial?
"In order to run this trial, we need 750 individuals who fit the specific bill. These people can be sourced from different clinical research sites, like #840-049 in West Palm Beach, Florida, and #840-046 in Los Angeles, California."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Clinical Research Site - Bradenton: < 24 hours
- Clinical Research Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger